Omentin (Intestinal Lactoferrin Receptor ITLN1) is an adipokine that is mainly secreted by the mesothelial cells lining visceral adipose tissues. It has been shown in previous studies that ovarian cancer cells down-regulate omentin which allows increased proclivity to spread to the omentum. Levels of serum omentin are decreased in patients with high-grade serous ovarian cancer (HGSOC) compared with patients with benign gynecologic diseases. Moreover, survival correlation studies showed that patients with lower serum omentin level at the time of first treatment experienced significantly shorter survival times than those with higher levels of omentin. CA-125 is currently the only biomarker used to monitor progression and re-occurrence of ovarian cancer. To our best knowledge, the relationship between omentin and CA-125 has not been investigated previously. We hypothesize that omentin may be a clinically useful adjunct to CA-125 in detecting recurrent ovarian cancer.

92 serum samples were collected prospectively from 27 HGSOC patients during the postoperative period until recurrence was detected. Patients had an average of 3.37 follow up visits and CA-125 levels were concurrently established. Recurrence was determined by imaging or an increase from baseline in CA-125 level. Samples were stored frozen at -80 degrees Celsius until use for this study. Circulating omentin levels were quantified using commercially available enzyme-linked immunosorbent assay (ELISA) kits. The results showed that 24 patients experienced a rise in CA-125 level during the postoperative period and 12 of these patients had an associated decrease in serum omentin level (average = 127.8 ng/mL). A significant negative correlation between omentin and CA-125 levels was observed (p = 0.02).

This study provides the first evidence that omentin may be a clinically useful adjunct to CA-125 in detecting recurrent ovarian cancer and warrants further investigation.

Citation Format: Kelsey Lewis, Chi Lam Au Yeung, Samuel Mok, Karen Lu. Omentin as an adjunct to CA-125 in detecting recurrent ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4661. doi:10.1158/1538-7445.AM2017-4661